Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer

T Sen, N Takahashi, S Chakraborty, N Takebe… - Nature Reviews …, 2024 - nature.com
Small-cell lung cancer (SCLC) has traditionally been considered a recalcitrant cancer with a
dismal prognosis, with only modest advances in therapeutic strategies over the past several …

Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies

K Kawasaki, N Rekhtman… - Nature Reviews …, 2023 - nature.com
Neuroendocrine neoplasms (NENs) can develop in almost any organ and span a spectrum
from well-differentiated and indolent neuroendocrine tumours (NETs) to poorly differentiated …

Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation

S Sivakumar, JA Moore, M Montesion, R Sharaf, DI Lin… - Cancer discovery, 2023 - AACR
Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal
survival outcomes. A major barrier in the field has been the relative paucity of human tumors …

Chromothripsis-mediated small cell lung carcinoma

N Rekhtman, SE Tischfield, CA Febres-Aldana… - Cancer …, 2025 - aacrjournals.org
Small cell lung carcinoma (SCLC) is a highly aggressive malignancy that is typically
associated with tobacco exposure and inactivation of RB1 and TP53 genes. Here, we …

Small cell lung carcinoma: current diagnosis, biomarkers, and treatment options with future perspectives

K Krpina, S Vranić, K Tomić, M Samaržija, L Batičić - Biomedicines, 2023 - mdpi.com
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid
proliferation, early dissemination, acquired therapy resistance, and poor prognosis. Early …

[HTML][HTML] Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity

E Redin, Á Quintanal-Villalonga, CM Rudin - Trends in Cancer, 2024 - cell.com
Small cell lung cancer (SCLC) is a devastating disease with high proliferative and metastatic
capacity. SCLC has been classified into molecular subtypes based on differential …

Systemic therapy for small-cell lung cancer: ASCO-Ontario health (cancer care Ontario) guideline

H Khurshid, N Ismaila, J Bian, R Dabney… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To provide evidence-based recommendations to practicing clinicians on the
management of patients with small-cell lung cancer. METHODS An Expert Panel of medical …

SAR-096: Phase II clinical trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL) and leiomyosarcoma (LMS)

S Movva, S Matloob, EA Handorf, E Choy… - Clinical Cancer …, 2024 - AACR
Purpose: Dedifferentiated liposarcoma (DDL) and leiomyosarcoma (LMS) are two common
subtypes of soft-tissue sarcoma, a rare group of diseases for which new treatments are …

PD‐L1 and nectin‐4 expression and genomic characterization of bladder cancer with divergent differentiation

DJ Martini, KB Case, D Gratz, K Pellegrini, E Beagle… - Cancer, 2024 - Wiley Online Library
Background Bladder cancer with divergent differentiation (BCDD) comprises a
heterogenous group of tumors with a poor prognosis, and differential expression of nectin‐4 …

Genetically-engineered mouse models of small cell lung cancer: the next generation

MG Oser, D MacPherson, TG Oliver, J Sage, KS Park - Oncogene, 2024 - nature.com
Small cell lung cancer (SCLC) remains the most fatal form of lung cancer, with patients in
dire need of new and effective therapeutic approaches. Modeling SCLC in an …